Gland Pharma gets USFDA’s approval for Eribulin Mesylate Injection

08 Apr 2024 Evaluate

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product). The Product is expected to be the first generic approval on the market, and the company expects to launch this product in the near term through its marketing partner. 

The Product has US sales of around $92 million for twelve months ending in February 2024, according to IQVIA. The company is co-developing several complex injectables, including this Product, with Orbicular Pharmaceutical Technologies.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1709.10 -18.85 (-1.09%)
30-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.30
Dr. Reddys Lab 6198.90
Cipla 1402.20
Zydus Lifesciences 957.00
Lupin 1645.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.